The most prevalent lung cancer, non-small cell lung cancer (NSCLC) has receptors for vasoactive intestinal peptide (VIP). Here the effects of a VIP antagonist (VIPhyb) on NSCLC growth were investigated. In vivo, when VIPhyb (10 ,ug, s.c.) was daily injected into nude mice, xenograft formation was significantly inhibited by -40%. In vitro, VIP (100 nM) stimulated colony formation -2-fold, whereas 1 ,uM VIPhyb inhibited colony formation by -50% when adenocarcinoma cel line NCI-H838 was used. The attenuation of tumor proliferation is receptor mediated, as VIPhyb inhibited specific 12sI-labeled VIP binding to cell lines NCI-H157 and NCI-H838 with an IC5s of 0.7 ,M. VIP (10 nM) increased the cAMP levels 5-fold when ceUl line NCI-H838 was used, and 10 ,uM VIPhyb inhibited the increase in cAMP caused by VIP. Northern blot analysis and radioimmunoassays have shown VIP mRNA and VIP-like immunoreactivity in NSCLC cells. These data suggest that VIP may be a regulatory peptide in NSCLC and that VIPhyb is a VIP receptor antagonist that inhibits proliferation.
VIPhyb inhibited specific 12sI-labeled VIP binding to cell lines NCI-H157 and NCI-H838 with an IC5s of 0.7 ,M. VIP (10 nM) increased the cAMP levels 5-fold when ceUl line NCI-H838 was used, and 10 ,uM VIPhyb inhibited the increase in cAMP caused by VIP. Northern blot analysis and radioimmunoassays have shown VIP mRNA and VIP-like immunoreactivity in NSCLC cells. These data suggest that VIP may be a regulatory peptide in NSCLC and that VIPhyb is a VIP receptor antagonist that inhibits proliferation.
Non-small cell lung cancer (NSCLC), which includes adenocarcinoma, large cell carcinoma, and squamous cell carcinoma, is the most prevalent type of lung cancer, killing ==110,000 people in the United States annually (1) . Even with current surgical and chemotherapeutic interventions, NSCLC patients have a median survival time of 5 years. Although the regulation of growth for NSCLC is poorly understood, previous investigations have shown that NSCLC cells possess receptor sites for vasoactive intestinal peptide (VIP; refs. 2 and 3), a substance with recognized effects on cellular proliferation and development (4) (5) (6) .
VIP, a 28-amino acid polypeptide, is derived from a 170-amino acid precursor protein (7, 8) . PreproVIP may be metabolized to VIP by trypsin-like enzymes, carboxypeptidase B-like enzymes, and peptidyl-a-monooxygenase (9) (10) (11) . VIP, which is amidated at the C terminus, is localized to neurons and endocrine cells in the central nervous system (CNS) and periphery of normal animals. Upon CNS administration, VIP modulates neuronal activity, stimulates adenylate cyclase activity, and regulates cerebral blood flow (12) . Also, VIP maintains survival of spinal cord neurons in primary culture (6) . In the periphery, endogenous VIP is present in nerves supplying airway smooth muscle as well as glands and pulmonary vessels within the normal adult lung (13) . VIP functions as a bronchodilator and relaxes pulmonary vascular smooth muscles (14) (15) (16) (17) . These actions may be mediated by the VIP receptors that have been detected in binding assays with plasma membranes derived from the rat, mouse, guinea pig, and human lung (18) (19) (20) . By in vitro autoradiographic techniques and lung slices, these VIP receptors have been localized to the alveoli and epithelium of the rat lung and pulmonary artery smooth muscle and alveolar walls of the human lung (21, 22) ; VIP is deficient in patients with bronchial asthma (23) .
In the malignant lung, high-affinity 125I-labeled VIP binding sites were detected in small cell lung cancer (SCLC) and NSCLC cell lines (2, 3, 24) . Also, high-affinity binding sites on SCLC were found for helodermin and pituitary adenylate cyclase-activating polypeptide (PACAP), which are both members of the VIP family in that they share structural similarity with VIP (25, 26) . VIP elevates intracellular cAMP and increases the secretion rate of bombesin-like peptides from SCLC cells (27) . Bombesin-like peptides stimulate SCLC but not NSCLC proliferation (28) .
Recently, a VIP-receptor antagonist was synthesized that is a hybrid peptide of neurotensin and VIP consisting of an N-terminal Lys-Pro-Arg-Arg-Pro-Tyr (designed to increase membrane permeability) followed by the C-terminal 22 amino acids of VIP (29, 30) . VIPhybrid (VIPhyb) is effective in blocking the actions of VIP in the CNS, but it is impotent at receptors present on lymphocytes (31) (32) (33) , thereby suggesting regional VIP receptor heterogeneity and significant pharmacological specificity for this peptide. Here the effects of VIPhyb on NSCLC cells were investigated.
METHODS
Cell Culture. Human lung cancer cell lines (NCI-H23, -H157, -H226, -H322, -H460, -H522, -H727, -H838, -H1299, and -H1512) were cultured in serum-supplemented medium at 370C [RPMI 1640 medium (Fisher Scientific) containing 10% heat-inactivated fetal bovine serum (GIBCO)]. The NSCLC cell lines were adherent and weekly were split 1:20 by using trypsin/EDTA (GIBCO). Routinely, the cells had >90% viability and were mycoplasma free. The cells were used when they were in the exponential growth phase.
Binding Studies. The ability of agents to inhibit 17-5I-VIP binding was investigated. NCI-H23, -H157, -H727, or -H838 cells were harvested after treatment with trypsin/EDTA and 5 x 104 cells were added to 24-well plates, which were pretreated with 10 ,ug of human fibronectin (Sigma). After a monolayer of cells had formed (3 days cAMP Assays. cAMP was assayed by radioimmunoassay as described (27) . Cell lines NCI-H727, -H838, or -H1299 were harvested and resuspended in SIT medium containing 1% bovine serum albumin, 1 mg of bacitracin per ml, and 100,uM isobutylmethylxanthine. After 5 min, the reaction was quenched by addition of an equal volume (0.5 ml) of ethanol. The samples were mixed and frozen at -80°C until assay. The samples were acetylated before the radioimmunoassay.
In Vitro Growth Assays. Growth assays were conducted with NCI-H226, -H727, -H838, or -H1299 cells and by the agarose cloning system described (28) . The base layer consisted of 3 ml of 0.5% agarose in SIT medium containing 5% fetal bovine serum in six-well plates. The top layer consisted of 3 ml of SIT medium in 0.3% agarose, the peptide(s) doubly concentrated, and 2 x 104 single viable cells. For each cell line and peptide concentration, triplicate wells were plated. After 2 weeks, 1 ml of 0.1% p-iodonitro tetrazolium violet was added and after 16 hr at 37°C the plates were screened for colony formation. The number of viable colonies >120 ,um in diameter was counted.
In Vivo Growth Assays. The ability of VIPhyb to inhibit xenograft formation in nude mice was investigated. Female athymic BALB/c nude mice, 4-5 weeks old, were housed in a pathogen-free temperature controlled isolation room and the diet consisted of autoclaved rodent chow and autoclaved water given ad libitum. NCI-H157, -H727, or -H838 cells (1 x 107) were injected s.c. into the right flank of each mouse. Palpable tumors were observed in =90% of the mice after 1 week. Phosphate-buffered saline (PBS) (100 ,ul), or VIPhyb (10 uglg/100 Il) was injected s.c. daily. The tumor volume (height x width x depth) was determined with calipers twice weekly and recorded. When the tumor became necrotic, the growth studies were terminated. The tumor was then excised and weighed.
RNA Measurements and Radioimmunoassays. The VIP mRNA was determined by Northern blot analysis. Total NSCLC RNA was isolated by the guanidinium isothiocyanate or urea/lithium chloride method (9) . Ten micrograms of denatured RNA was separated in a 0.66 M formaldehyde/1% agarose gel. The RNA was blotted onto a nitrocellulose membrane overnight and the membrane was hybridized with a complementary RNA probe for a human VIP-encoding exon (10) . The probe was subcloned in the bacterial plasmid vector pGEM-1, labeled with [32P]UTP according to the Promega Biotec protocol, and the blot was hybridized. After the blot was washed, the film exposure time was routinely 16 hr at -70°C.
For VIP radioimmunoassays, lung cancer cell lines were extracted by boiling in 2 M acetic acid, lyophilized, resuspended in phosphate-buffered saline containing 1% bovine serum albumin and rabbit anti-VIP antiserum (1:20,000) as well as 5000 cpm of 125I-VIP (2200 Ci/mmol), and incubated for 16 hr at 4°C. Goat anti-rabbit antiserum was added at a dilution of 1:10 and normal rabbit serum was added at a dilution of 1:100; 12% polyethylene glycol was added to form a stable precipitate, which was collected by centrifugation at 1000 x g and assayed with a y-counter. The sensitivity of the assay was 1 fmol of VIP and the antiserum had strong cross-reactivity with VIP and VIP-(10-28), but not to secretin, PACAP, glucagon, or thymosin al.
RESULTS
VIP Stimulates NSCLC Proliferation in Vitro. The effects of VIP on NSCLC growth were investigated with a clonagenic assay using adenocarcinoma cell line NCI-H838. When colonies >120 ,um in diameter were counted, 100 nM VIP significantly stimulated colony number, with 10 nM VIP slightly increasing growth (Fig. 1 Top) . Similar data were observed for NCI-H226 (adenocarcinoma), NCI-H1299 (large cell carcinoma), and NCI-H727 (lung carcinoid) cell lines. Large viable colonies formed in the absence of additions (Fig. 1 Middle) and VIP increased the number and size of the colonies.
VIP Is Synthesized by NSCLC. The presence of VIP mRNA and VIP immunoreactivity was investigated. By using VIPspecific RNA probes (10, 11) and Northern blot hybridization, a major band at 2.1 kb and a minor band at 5 kb (Fig. 2) were detected in total RNA isolated from NCI-H727. Previous studies of rat brain and human tumors indicated that the 2.1-and 5-kb bands correspond to VIP mRNA and VIP RNA that was not properly spliced; the VIP gene has six introns (9-11). A VIP Antagonist Inhibits NSCLC Growth in Vitro. The ability of VIPhyb to block VIP receptors was investigated. In the presence of 1 ,uM VIPhyb, the number and size of the NCI-H838 colonies grown in cell culture were reduced (Fig.  1 Bottom) . Also, VIPhyb slightly decreased colony number at 100 nM and significantly reduced colony number at 1 and 10 ,uM (Fig. 1 Top) . Similar data were obtained by using the cell lines NCI-H226 (adenocarcinoma), NCI-H1299 (large cell carcinoma), and NCI-H727 (lung carcinoid). Also, 100 nM VIP increased the number of NCI-H838 colonies from 21 to 44, and in the presence of VIP plus 1 uM VIPhyb, only 23 colonies formed. These data suggest that VIPhyb may antagonize the growth stimulation caused by endogenous or exogenous VIP.
To support the hypothesis that antagonist action was due to inhibition of VIP receptors on the tumor cells, radioligand binding studies were carried out. As shown in Fig. 3 Top, VIPhyb and VIP blocked specific 125I-VIP binding to NSCLC cell line NCI-H838 in a concentration-dependent manner. The concentrations of VIPhyb, PACAP, and VIP required to inhibit 50o of the specific 125I-VIP bound (IC50) were 0.7 ,.M, 20 nM, and 7 nM. VIP-(10-28) was less potent and inhibited specific 125I-VIP binding with an IC5o value of 5 ,uM. Similar data were obtained for NCI-H23 (adenocarcinoma), -H157 (squamous cell carcinoma), and -H727 (lung carcinoid) cells.
The effects of VIPhyb on second messenger production were investigated. VIP elevated the cAMP levels in a concentration-dependent manner (ED5o = 1 nM; Fig. 3 Middle).
In contrast, VIPhyb (10 ,uM) completely inhibited the cAMP production elicited by 1 nM VIP (Fig. 3 Middle) and attenuated the increase in cAMP caused by 10 nM VIP with a half-maximal concentration of6 ,uM (Fig. 3 VIPhyb was added to NCI-H838 in the presence ofincreasing amounts of VIP, the dose-response curve was shifted to the right (ED50 = 5 nM; Fig. 3 Middle), consistent with the action of a competitive antagonist. Similar data were obtained by using cell lines NCI-H1299 and -H727. Finally, VIPhyb had no agonistic activity on cAMP production (Fig. 3 Bottom).
Together these data support the conclusion that VIPhyb antagonizes VIP receptors on NSCLC cells. VIPhyb Inhibits Lung Cancer Growth in Vivo. Also, the effects of VIPhyb were investigated on NSCLC xenograft formation. Fig. 4 3. VIPhyb inhibited tumor growth in a dose-dependent manner and at week 3 the mean tumor volumes were 433 and 255 mm3 using 1 and 10 ,ug of VIPhyb, respectively. These data indicate that 0.1 ,ug of VIPhyb slowed NSCLC growth, whereas 1 and 10 ug significantly inhibited NSCLC xenograft formation. The effects of the VIP hybrid antagonist were reversible in that removal of the antagonist resulted in a tumor growth rate similar to that of control animals. If the tumors were excised at the end of the experiment, the mean tumor weight was significantly reduced in the nude mice injected with 1 and 10 ug of VIPhyb. In addition, Table 1 shows that with NCI-H157 (squamous cell carcinoma), daily administration of the VIPhyb (10 ,ug/day s.c.) significantly inhibited xenograft formation. At the end of the experiment, the total weight of nude mice treated with 10 ,ug of VIPhyb was similar, whereas the xenograft weight was significantly reduced. 
DISCUSSION
The present study indicates that a VIP antagonist, VIPhyb, can attenuate the growth of lung cancer cells both in cell culture and in vivo. The specificity and potency of this peptide suggest that such a strategy may be effective at inhibiting the growth of these tumors by antagonizing the ability of VIP-like peptides that bind to VIP receptors. The mechanisms by which VIP mediates its proliferative effects and VIPhyb exerts its antagonistic effects are receptor mediated. Thus, VIPhyb inhibited specific 1251-VIP binding to NCI-H838 with an IC50 value of 0.7 ,uM and binds with =7-fold greater affinity than does VIP-(10-28). The affinity of VIPhyb for lung cancer receptors is "'10-fold lower than its affinity for the CNS cAMP-associated VIP receptor but is much greater than that of the lymphoid cell VIP receptor, suggesting tissue specificity (31) . In the embryonic peripheral nervous system, VIP stimulates mitosis at concentrations similar to those required to inhibit lung cancer proliferation (4) . Recently, the peripheral VIP receptor was cloned and found to contain 459 amino acid residues and 7 hydrophobic domains (34) . It has a structure reminiscent of other guanine nucleotide binding protein-coupled receptors such as the bombesin/gastrin-releasing peptide (BN/GRP) receptor (35, 36) .
VIPhyb may inhibit binding to other receptors of the VIP family. 1251-PACAP-27 binds with high affinity to lung cancer cell lines (26) . Specific 125I-PACAP-27 binding is inhibited with -2 orders of magnitude greater affinity by PACAP-27 than by VIP. Also, VIPhyb inhibits 125I-PACAP-27 binding with approximately the same affinity as it does 1251-VIP binding; VIPhyb has no effect on SCLC BN/GRP receptors. Therefore, VIPhyb may be useful at inhibiting PACAP in addition to VIP receptors. Also, helodermin receptors are on SCLC cells (25) , and the effect of VIPhyb on these receptors is unknown.
The antagonistic effects of VIPhyb were also apparent at the level of VIP-stimulated cAMP formation. Approximately 6 ,uM VIPhyb was required to half-maximally inhibit the increase in cAMP caused by 10 nM VIP; VIP had no effects on phosphatidylinositol turnover at doses ranging from 0.1 to 1000 nM. This is approximately an order of magnitude more VIPhyb than was required to inhibit 125I-VIP binding; however, the binding experiments used only 0.2 nM 125I-VIP. Also, the ED50 for VIP to elevate cAMP increased from 1 to 5 nM in the presence of 10 ,uM VIPhyb. Because 74 nM VIPhyb was required to inhibit the cAMP increase caused by 1 ,uM VIP in the CNS (8) , VIPhyb is less potent in NSCLC cells. VIP- (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) was approximately an order of magnitude less potent than VIPhyb at inhibiting VIP-stimulated cAMP (T.W.M., unpublished data).
NSCLC cells have amplification and increased expression of the c-myc and Ki-ras oncogenes (37, 38) . NSCLC cells produce type a transforming growth factor (TGF-a) and have epidermal growth factor (EGF) receptors; the growth of NSCLC is inhibited by TGF-a and EGF receptor monoclonal antibodies (39) (40) (41) . Lung cancer cells may proliferate because ofthe abundance ofoncogenes and growth factors. The effects of VIP on growth factor gene expression remain to be investigated. Preliminary data indicate that VIP stimulates lung cancer c-fos mRNA levels and the increase in c-fos caused by VIP was inhibited by VIPhyb (M.D., unpublished data). VIP may stimulate early response genes by activation of protein kinase A, which in turn alters oncogene expression.
VIPhyb inhibited the growth of NSCLC. Other investigators have found that VIP stimulates (4-6) or inhibits (42) growth and development. Thus, the effects of VIP are complex and depend on cell type, dose, and assay used. Here VIPhyb inhibited and VIP stimulated the growth of NSCLC.
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